Pfizer CEO: Transforming Drug Discovery, Lessons from China and Leading with Optimism

Pfizer CEO Albert Bourla outlines the company’s strategic pivot toward innovative science, emphasizing the role of organizational resilience and cultural transformation in navigating post-pandemic challenges. The discussion highlights the integration of antibody-drug conjugates through the acquisition of Seagen and the pursuit of obesity treatments via Metsera to maintain competitive momentum. Bourla identifies artificial intelligence as a critical driver for accelerating drug discovery and manufacturing, while stressing the need for AI literacy to overcome internal inertia. Addressing global competition, he argues that the U.S. pharmaceutical industry must prioritize outperforming China’s rapid scientific output through increased focus, speed, and technological investment. Ultimately, leadership success hinges on fostering a culture that empowers employees, maintains optimism, and prioritizes long-term scientific breakthroughs over short-term financial gains.